drugset / Trial / NCT06700499
A Study to Evaluate the Efficacy and Safety of AK120 in Subjects With Moderate to Severe Atopic Dermatitis
NaSingle-groupOpen-labelTreatment
Summary
This is a multicenter, open label phase II clinical study to evaluate the efficacy and safety of AK120 in the treatment of subjects with moderate to severe atopic dermatitis.
Timeline
- Start
- 2024-07-08
- Primary completion
- 2025-07-31
- Completion
- 2025-09-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AK120 | Monoclonal antibody | 300 mg | Subcutaneous |